By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



ul. Ostatnia 1c

Krak√≥w    31-444  Poland
Phone: 48-12-410-7380 Fax: 48-12-410-7382



Company News
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients 8/8/2017 9:40:03 AM
Selvita And Menarini Group Announce Global License Agreement For Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24 3/28/2017 11:16:28 AM
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia 3/17/2017 7:22:41 AM
Selvita To Present New Data From Its Oncology Programs At The Upcoming AACR Annual Meeting 2017 3/13/2017 8:40:02 AM
Selvita Signs A Significant Collaboration With UCSF 8/9/2016 9:52:06 AM
Selvita Files IND Application For Its Novel, Dual PIM/FLT3 Inhibitor In AML 4/18/2016 10:00:37 AM
Selvita Bridges Krakow And San Francisco 3/11/2016 9:22:54 AM
Selvita Opens New Research Site In Poznan 2/4/2016 9:36:12 AM
Selvita Will Present At the 18th Annual BIO CEO & Investor Conference 2016 2/1/2016 10:02:42 AM
Merck & Co. (MRK) And Selvita Announce Drug Discovery Collaboration 11/2/2015 10:43:19 AM